99592-53-7 Usage
General Description
2-(Bromomethyl)-5-chloro-1-benzothiophene is a chemical compound with the molecular formula C9H6BrClS. It is a halogenated benzothiophene derivative, which is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. The compound is a white to light yellow solid, with a molecular weight of 241.57 g/mol. It is primarily used as an intermediate in the production of various organic compounds, and it is known for its reactivity in cross-coupling reactions and other organic transformations. This chemical is also known for its potential biological activities, making it a valuable tool in medicinal chemistry research and drug development. However, it is important to handle and use this compound with caution due to its potential hazards and toxicological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 99592-53-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,9,5,9 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 99592-53:
(7*9)+(6*9)+(5*5)+(4*9)+(3*2)+(2*5)+(1*3)=197
197 % 10 = 7
So 99592-53-7 is a valid CAS Registry Number.
99592-53-7Relevant articles and documents
ANTI-INFECTIVE COMPOUNDS
-
, (2015/02/25)
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
Hypoglycemic imidazoline compounds
-
Page/Page column 24, (2010/02/05)
This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.
Hypoglycemic imidazoline compounds
-
, (2008/06/13)
This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.